Nuclear factor kappa b and matrix metalloproteinase induced receptor cleavage in the spontaneously hypertensive rat

Hypertension

Volumn 57, Issue 2, 2011, Pages 261-268

  Wu, Kwan I Sharon ^a   Schmid Schönbein, Geert W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

adrenergic receptor; matrix metalloproteinases; microcirculation; pyrrolidine dithiocarbamate; receptor cleavage

Indexed keywords

BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; PYRROLIDINE DITHIOCARBAMATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; CONTROLLED STUDY; ENZYME ACTIVITY; HEART; HEART MUSCLE; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY HOMOGENATE; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; ZYMOGRAPHY;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; HYPERTENSION; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NF-KAPPA B; PYRROLIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, BETA-2; SPECIES SPECIFICITY; THIOCARBAMATES;

EID: 79551480400     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.110.158709     Document Type: Article

References (52)

1. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995; 25:155-161.
2. Johansson BB. Hypertension mechanisms causing stroke. Clin Exp Pharmacol Physiol. 26:563-565.
3. Li JJ, Fang CH, Hui RT. Is hypertension an inflammatory disease? Med Hypotheses. 2005;64:236-240.
4. Luft FC, Mervaala E, Müller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage: A new transgenic approach to an old problem. Hypertension. 1999;33:212-218.
5. Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood pressure: epidemiologic and biological evidence. J Hum Hypertens. 2003;17:223-230.
6. Schmid-Schönbein GW, Seiffge D, DeLano FA, Shen K, Zweifach BW. Leukocyte counts and activation in spontaneously hypertensive and nor-motensive rats. Hypertension. 1991;17:323-330.
7. Hong HJ, Wu CC, Yen MH. Pyrrolidine dithiocarbamate improves the septic shock syndromes in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1998;25:600-606.
8. Lim HH, DeLano FA, Schmid-Schönbein GW. Life and death cell labeling in the microcirculation of the spontaneously hypertensive rat. J Vasc Res. 2001;38:228-236.
9. Rodríguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappab prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315:51-57.
10. Kobayashi N, DeLano FA, Schmid-Schönbein GW. Oxidative stress promotes endothelial cell apoptosis and loss of microvessels in the spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol. 2005;25: 2114-2121.
11. Shen K, DeLano FA, Zweifach BW, Schmid-Schönbein GW. Circulating leukocyte counts, activation, and degranulation in dahl hypertensive rats. Circ Res. 1995;76:276-283.
12. DeLano FA, Forrest MJ, Schmid-Schönbein GW. Attenuation of oxygen free radical formation and tissue injury during experimental inflammation by P-selectin blockade. Microcirculation. 1997;4:349-357.
13. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40:1362-1378.
14. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circu Res. 2003;92:827-839.
15. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90: 251-262.
16. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75: 346-359.
17. Rodrigues SF, Tran ED, Fortes ZB, Schmid-Schönbein GW. Matrix metalloproteinases cleave the beta2 -adrenergic receptor in the spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2010;299: H25-H35.
18. DeLano FA, Schmid-Schönbein GW. Proteinase activity and receptor cleavage: mechanism for insulin resistance in the spontaneously hypertensive rat. Hypertension. 2008;52:415-423.
19. Tran ED, DeLano FA, Schmid-Schönbein GW. Enhanced matrix metal-loproteinase activity in the spontaneously hypertensive rat: VEGFR-2 cleavage, endothelial apoptosis, and capillary rarefaction. J Vasc Res. 2010;47:423-431.
20. Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology. 2000;61:167-173.
21. Monopoli A, Conti A, Forlani A, Ongini E. Beta1 and beta2 adreno-ceptors are involved in mediating vasodilation in the human coronary artery. Pharmacol Res. 1993;27:273-279.
22. Iaccarino G, Cipolletta E, Fiorillo A, Annecchiarico M, Ciccarelli M, Cimini V, Koch WJ, Trimarco B. Beta(2)-adrenergic receptor gene delivery to the endothelium corrects impaired adrenergic vasorelaxation in hypertension. Circulation. 2002;106:349-355.
23. Bengtsson K, Orho-Melander M, Melander O, Lindblad U, Ranstam J, Råstam L, Groop L. Beta(2)-adrenergic receptor gene variation and hypertension in subjects with type 2 diabetes. Hypertension. 2001;37: 1303-1308.
24. Bray MS, Krushkal J, Li L, Ferrell R, Kardia S, Sing CF, Turner ST, Boerwinkle E. Positional genomic analysis identifies the beta2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation. 2000;101:2877-2882.
25. Dungan JR, Conley YP, Langaee TY, Johnson JA, Kneipp SM, Hess PJ, Yucha CB. Altered beta-2 adrenergic receptor gene expression in human clinical hypertension. Biol Res Nurs. 2009;11:17-26.
26. Kato N, Sugiyama T, Morita H, Kurihara H, Sato T, Yamori Y, Yazaki Y. Association analysis of beta(2)-adrenergic receptor polymorphisms with hypertension in Japanese. Hypertension. 2001;37:286-292.
27. Fabunmi RP, Baker AH, Murray EJ, Booth RF, Newby AC. Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. Biochem J. 1996;315:335-342.
28. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: Association of MMP induction with bone resorption. Endocrinology. 1998;139: 1338-1345.
29. Gupta S, Young D, Sen S. Inhibition of NFkappab induces regression of cardiac hypertrophy, independent of blood pressure control, in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 2005;289: H20-H29.
30. Maulik N, Sato M, Price BD, Das DK. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS letters. 1998;429:365-369.
31. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NFkappa B/I kappa B family: Intimate tales of association and dissociation. Genes Dev. 1995;9:2723-2735.
32. Schreck R, Meier B, Männel DN, Droge W, Baeuerle PA. Dithiocar-bamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175:1181-1194.
33. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr. Requirement of NFkappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science. 1997;278: 1812-1815.
34. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 1999;45:7-17.
35. Pinkus R, Weiner LM, Daniel V. Role of oxidants and antioxidants in the induction of AP-1, NFkappa B, and glutathione S-transferase gene expression. J Biol Chem. 1996;271:13422-13429.
36. Rodríguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Chávez M, Herrera-Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol. 2002;282:F191-F201.
37. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NFkappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35:193-201.
38. Hong HJ, Loh SH, Yen MH. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol. 2000;131:631-637.
39. Li Q, Van Antwerp D, Mercurio F, Lee KF, Verma IM. Severe liver degeneration in mice lacking the Ikappa kinase 2 gene. Science. 1999; 284:321-325.
40. Quiroz Y, Bravo J, Herrera-Acosta J, Johnson RJ, Rodriguez-Iturbe B. Apoptosis and nf[kgr]b activation are simultaneously induced in renal tubulointerstitium in experimental hypertension. Kidney Int. 2003;64: S27-S32.
41. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401. (Pubitemid 24076725)
42. Chanutin A, Barksdale E. Experimental renal insuffciency produced by partial nephrectomy: Ii. Relationship of left ventricular hypertrophy, the width of the cardiac muscle fiber and hypertension in the rat. Arch Intern Med. 1933;52:739-751.
43. Silverthorn DU, Ober WC, Garrison CW, Silverthorn AC, Johnson BR. Human physiology: an integrated approach. San Francisco, CA: Daryl Fox; 2004.
44. Bataillard A, Renaudin C, Sassard J. Silica attenuates hypertension in Lyon hypertensive rats. J Hypertens. 1995;13:1581-1584. (Pubitemid 26015778)
45. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NFkappa B reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res. 2001;50:556-565.
46. Liu SF, Ye X, Malik AB. In vivo inhibition of nuclear factor-kappa B activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol. 1997; 159:3976-3983.
47. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: A functional role for receptor-receptor interaction in vivo. Circulation. 2003; 108:1611-1618.
48. Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens. 2003;21:1719-1727.
49. Hultstrom M, Leh S, Skogstrand T, Iversen BM. Upregulation of tissue inhibitor of metalloproteases-1 (TIMP-1) and procollagen-n-peptidase in hypertension-induced renal damage. Nephrol Dial Transplant. 2007; 2007:1-8.
50. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, Wood AJ. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345:1030-1035.
51. Wang G, Owens SA, Yu P, Asico LD, Hopfer U, Jose PA, Xu J. Endogenous beta-2 adrenergic receptor involved in abnormal proximal tubule sodium reabsorption in shr. American J Hypertens. 2005;18: A136-A137.
52. Aoki M, Nata T, Morishita R, Matsushita H, Nakagami H, Yamamoto K, Yamazaki K, Nakabayashi M, Ogihara T, Kaneda Y. Endothelial apo-ptosis induced by oxidative stress through activation of NFkappaB: anti-apoptotic effect of antioxidant agents on endothelial cells. Hypertension. 2001;38:48-55.